199 related articles for article (PubMed ID: 23010260)
1. Hemophilic arthropathy in patients with von Willebrand disease.
van Galen KP; Mauser-Bunschoten EP; Leebeek FW
Blood Rev; 2012 Nov; 26(6):261-6. PubMed ID: 23010260
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis and von Willebrand's disease (vWD).
Abshire TC
Thromb Res; 2006; 118 Suppl 1():S3-7. PubMed ID: 16580053
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis in von Willebrand disease.
Berntorp E
Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
[TBL] [Abstract][Full Text] [Related]
4. Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study.
van Galen KPM; de Kleijn P; Foppen W; Eikenboom J; Meijer K; Schutgens REG; Fischer K; Cnossen MH; de Meris J; Fijnvandraat K; van der Bom JG; Laros-van Gorkom BAP; Leebeek FWG; Mauser-Bunschoten EP;
Haematologica; 2017 Sep; 102(9):1486-1493. PubMed ID: 28572165
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
Berntorp E
Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
[TBL] [Abstract][Full Text] [Related]
6. Orthopaedic surgery in patients with von Willebrand disease.
Siboni SM; Biguzzi E; Solimeno LP; Pasta G; Mistretta C; Mannucci PM; Peyvandi F
Haemophilia; 2014 Jan; 20(1):133-40. PubMed ID: 23992395
[TBL] [Abstract][Full Text] [Related]
7. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study.
van Galen KPM; Sanders YV; Vojinovic U; Eikenboom J; Cnossen MH; Schutgens REG; van der Bom JG; Fijnvandraat K; Laros-Van Gorkom BAP; Meijer K; Leebeek FWG; Mauser-Bunschoten EP;
Haemophilia; 2015 May; 21(3):e185-e192. PubMed ID: 25854528
[TBL] [Abstract][Full Text] [Related]
8. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept.
Berntorp E; Abshire T;
Thromb Res; 2006; 118 Suppl 1():S19-22. PubMed ID: 16545435
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of prophylactic treatment in von Willebrand disease.
Lethagen S
Thromb Res; 2006; 118 Suppl 1():S9-11. PubMed ID: 16616322
[TBL] [Abstract][Full Text] [Related]
10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
11. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
12. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
13. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.
Foster PA
Thromb Haemost; 1995 Nov; 74(5):1370-8. PubMed ID: 8607125
[TBL] [Abstract][Full Text] [Related]
14. Type 3 von Willebrand disease: assessment of complications and approaches to treatment -- results of a patient and Hemophilia Treatment Center Survey in the United States.
Sumner M; Williams J
Haemophilia; 2004 Jul; 10(4):360-6. PubMed ID: 15230950
[TBL] [Abstract][Full Text] [Related]
15. The role of prophylaxis in the management of von Willebrand disease: today and tomorrow.
Abshire T
Thromb Res; 2009 Nov; 124 Suppl 1():S15-9. PubMed ID: 19944256
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis.
van Galen KPM; Timmer M; de Kleijn P; Leebeek FWG; Foppen W; Schutgens REG; Eikenboom J; Meijer K; Fijnvandraat K; Laros-van Gorkom BAP; Twisk JW; Mauser-Bunschoten EP; Fischer K;
Thromb Haemost; 2018 Oct; 118(10):1690-1700. PubMed ID: 30273954
[TBL] [Abstract][Full Text] [Related]
19. Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes.
Siegmund B; Richter H; Pollmann H
Haemophilia; 2007 Jan; 13(1):21-5. PubMed ID: 17212720
[TBL] [Abstract][Full Text] [Related]
20. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
